…
Vitrafy Life Sciences Limited engages in the research, development, and commercialization of cryopreservation solutions in Australia. It offers cryopreservation medical devices, including freezers, thawers, and packaging solutions. The company also provides the LifeChain software platform, which controls, trace, tracks, and monitors quality of cryopreserved biomaterials, as well as the Guardion, non-medical hardware device. Its cryopreservation technology is used various applications, such as blood platelets, cell and gene therapies, and aquaculture and bovine breeding programs. Vitrafy Life Sciences Limited was incorporated in 2017 and is based in Melbourne, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Vitrafy Life Sciences Ltd is an Australia-listed company in the life sciences sector; public disclosures are limited about its specific operations. Long-term growth drivers may include successful development of any underlying technologies or products, regulatory approvals, and commercial partnerships, and investors may find exposure to potential biotechnology upside and sector diversification.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Income before tax | -16.17M | -32.71M | -10.43M | -7.81M | -7.66M |
| Net income | -16.17M | -32.71M | -10.43M | -7.81M | -7.66M |
| Selling general administrative | 16.14M | 7.34M | 2.68M | 1.84M | 3.63M |
| Gross profit | 0.17M | 0.07M | 0.04M | 0.03M | - |
| Reconciled depreciation | 0.12M | 0.15M | - | - | - |
| Operating income | -20.44M | -16.57M | -10.67M | -9.16M | -6.44M |
| Interest expense | 0.00M | 6.49M | 10.43M | 4.99M | 2.73M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | 0.80M | 0.77M | - | - | - |
| Net interest income | 0.78M | -5.72M | -10.43M | -4.99M | -2.73M |
| Total revenue | 0.17M | 0.07M | 0.04M | 0.03M | - |
| Total other income expense net | 3.49M | -10.49M | 10.68M | 6.34M | 1.51M |
| Net income from continuing ops | -16.17M | -32.71M | -10.43M | -7.81M | -7.66M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Total assets | 43.21M | 31.84M | 41.33M | 0.00M | 0.00M |
| Other current assets | - | 0.98M | 0.38M | - | - |
| Total liab | 2.10M | 3.08M | 1.34M | 0.00M | 0.00M |
| Total stockholder equity | 41.11M | 28.77M | 39.99M | 0.00M | 0.00M |
| Capital stock | 117.66M | 89.69M | 86.90M | - | - |
| Retained earnings | -79.54M | -63.37M | -47.42M | - | - |
| Cash | 26.10M | 19.52M | 37.97M | - | - |
| Total current liabilities | 1.78M | 2.72M | 0.85M | 0.00M | 0.00M |
| Total current assets | 42.38M | 31.25M | 40.59M | 0.00M | 0.00M |
| Short term investments | 15.07M | 10.07M | - | - | - |
| Net receivables | 0.11M | 0.06M | - | - | - |
| Accounts payable | 1.27M | 0.56M | 0.40M | - | - |
| Non currrent assets other | - | - | -0.00M | - | - |
| Non current assets total | 0.84M | 0.59M | 0.74M | 0.00M | 0.00M |
| Capital lease obligations | 0.30M | 0.39M | 0.47M | - | - |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Investments | -5.00M | -10.07M | -0.01M | -0.09M | -0.49M |
| Net borrowings | - | - | 12.00M | 5.91M | - |
| Total cash from financing activities | 27.88M | 31.99M | 11.50M | 5.80M | -0.06M |
| Net income | -16.17M | -32.71M | -6.76M | -7.81M | -7.66M |
| Change in cash | 6.57M | 13.11M | 4.69M | 0.76M | -6.42M |
| Begin period cash flow | 19.52M | 6.41M | 1.72M | 0.96M | 7.38M |
| End period cash flow | 26.10M | 19.52M | 6.41M | 1.72M | 0.96M |
| Issuance of capital stock | 30.00M | 35.32M | 0.27M | 0.09M | - |
| Sale purchase of stock | -2.03M | -3.25M | - | - | - |
| Capital expenditures | 0.54M | 0.00M | 0.01M | 0.09M | 0.49M |
| Free cash flow | -16.31M | -8.80M | -6.80M | -5.05M | -6.36M |
Sector: Technology Industry: Software - Infrastructure
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
|---|---|---|---|---|---|---|---|
| VFY Vitrafy Life Sciences Ltd |
-0.02 0.81% |
2.45 | - | - | 893.81 | 4.64 | 887.51 |
| XYZ Block, Inc |
-2.22 1.78% |
122.66 | 111.51 | 15.77 | 2.89 | 2.22 | 1.63 |
| MP1 Megaport Ltd |
-0.69 3.89% |
17.06 | - | 138.89 | 13.81 | 4.10 | 12.09 |
| CCL Cuscal Ltd |
-0.07 1.17% |
5.89 | 26.77 | 20.28 | 1.97 | 2.73 | 5.15 |
| AXQ Aura Consolidated Group, Inc. |
0.02 0.58% |
3.48 | - | - | 3.78 | - | 5.49 |
Vitrafy Life Sciences Limited engages in the research, development, and commercialization of cryopreservation solutions in Australia. It offers cryopreservation medical devices, including freezers, thawers, and packaging solutions. The company also provides the LifeChain software platform, which controls, trace, tracks, and monitors quality of cryopreserved biomaterials, as well as the Guardion, non-medical hardware device. Its cryopreservation technology is used various applications, such as blood platelets, cell and gene therapies, and aquaculture and bovine breeding programs. Vitrafy Life Sciences Limited was incorporated in 2017 and is based in Melbourne, Australia.
| Name | Title | Year Born |
|---|---|---|
| Mr. Brenton Michael Leslie Owens | Co-Founder, MD, CEO & Executive Director | NA |
| Mr. Simon Thomas Martin | Chief Financial Officer | NA |
| Mr. Michael Sapountzis AGIA, B.Com., L.L.B., M.A.I.C.D. | Company Secretary | NA |
| Dr. Heather Pidcoke | Chief Science Officer | NA |
| Mr. Timothy P. Costello | EVP& Chief Commercial Officer | NA |
| Mr. Timothy P. Costello | EVP & Chief Commercial Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.